Status:
NOT_YET_RECRUITING
Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome
Lead Sponsor:
New Valley University
Conditions:
Antiphospholipid Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease cour...
Detailed Description
APS may manifest as a primary, isolated condition or as a secondary disorder in conjunction with other autoimmune diseases, notably systemic lupus erythematosus (SLE) . The syndrome presents in two pr...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adults (age ≥18 years)
- Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and/or pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant)
- Exclusion criteria:
- Current infection or inflammatory condition unrelated to APS
- Hematological malignancies or other blood disorders
- Recent blood transfusion or platelet-altering medications other than APS treatments
Exclusion
Key Trial Info
Start Date :
November 27 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07142239
Start Date
November 27 2025
End Date
June 30 2027
Last Update
August 26 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.